Popular on TelAve
- Wellness Technology Distributor Helping People Set Up Wellness Center Businesses - 306
- TechHouse Earns Highly Selective Microsoft Support Badge - 297
- ParkLens Launches AI-Powered Parking Sign Decoder to Help Drivers Avoid Costly Parking Tickets - 275
- Curious About Mensa? DFW Event Offers a 1-Day Immersion - 253
- How Strategic WooCommerce Development and Digital Marketing Helped a Fashion Ecommerce Business Increase Revenue by 3X - 223
- USA Med Bed Helping Home Care Patients with Refurbished Hill Rom Hospital Beds - 168
- Bangxing Silicone Revolutionizes Silicone Baby Product Partnerships: Low MOQ Support + VIP Long-Term Win-Win Programs
- KLEKT Announces Appointment of Jay Kimpton to Board of Directors
- All About Technology Celebrates 25 Years of Bridging Detroit's Digital Divide
- Community, Conservation & Waterwise Inspiration Bloom on June 6
Similar on TelAve
- Entering the $69 Billion Animal Health Market, Delivering Record Growth, AI-Driven Healthcare Innovation, and Targeting $200 Million Revenue by 2029
- FDA-Cleared AI Neuropsychiatry Platform, Million-Dose Ketamine Manufacturing and Presidential Psychedelic Initiative Drive Growing Momentum for NRXP
- Accelerating Toward Commercialization as FDA Momentum, AI Neurotherapy & Manufacturing Expansion Drive Multi-Catalyst Growth Story; N A S D A Q: NRXP
- Medical Experts Highlight the Importance of Second Opinions in Death Investigations
- NRx Pharmaceuticals (N A S D A Q: NRXP) Accelerates Into National Spotlight as Manufacturing Launch, Federal Policy & AI-Driven Breakthroughs Converge
- More Life Summit 2026 Announces Gary Brecka & Mr. Olympia Derek Lunsford as First Speakers for Miami Event
- Presidential Acceleration of Psychedelic Therapies Enters a Defining Moment as Federal Policy, FDA Alignment & Breakthrough Neurotechnology Converge
- Dual-Engine Growth Strategy Unleashed Targeting a $9.1B Market and the Exploding AI Biotech Revolution: KALA BIO (N A S D A Q: KALA)
- AI-Driven Neurotechnology Expansion as FDA Path Clears and New Defense Initiative Emerges for NRx Pharmaceuticals (N A S D A Q: NRXP)
- Charging Into the $30 Billion Heart Failure Market with Late-Stage Momentum, Breakthrough Data, & Strong Financial Backing: Cardiol Therapeutics $CRDL
Philadelphia Scientist Roohid Parast Advances IBD Research at Johnson & Johnson
TelAve News/10896998
Translational scientist pursues MBA with AI concentration, bridging clinical biomarker research and emerging technology
PHILADELPHIA - TelAve -- Roohid Parast, a scientist at Johnson and Johnson in Springhouse, Pennsylvania, is expanding his expertise by pursuing a Masters of Business Administration with a concentration in Artificial Intelligence, expected to be completed by the end of 2026.
Parast currently works within J&J's translational medicine group, supporting the clinical development of compounds targeting inflammatory bowel disease, psoriasis, and psoriatic arthritis. His responsibilities include generating and analyzing proteomic and transcriptomic datasets from human clinical samples that directly inform dose selection decisions and mechanism of action assessments in active drug trials. Platforms he works with include Meso Scale Discovery immunoassays, digital spatial profiling, and single-cell RNA sequencing from FFPE tissue.
More on TelAve News
His focus on IBD is particularly relevant given that ulcerative colitis and Crohn's disease affect an estimated 3 million Americans, with a significant portion failing to respond to existing biologic therapies. Parast holds a BS in Biochemistry from Temple University, and prior to his role at J&J, worked as an Associate Scientist II at QPS and in biopharmaceutical manufacturing at GSK.
Beyond his biomarker work, Parast is developing a deeper interest in fundamental biology, specifically the interleukin-23 receptor (IL-23R) pathway, which plays a central role in the inflammatory cascade underlying IBD and psoriatic disease. His MBA concentration in Artificial Intelligence reflects a conviction that the future of drug development will be shaped by scientists who can speak both the language of biology and machine learning.
Outside of his pharmaceutical career, Parast holds an ACSM personal trainer certification and writes about the science of training, inflammation, and recovery. His professional profile is at roohidparast.github.io and his research profile is at researchgate.net/profile/Roohid-Parast.
Parast currently works within J&J's translational medicine group, supporting the clinical development of compounds targeting inflammatory bowel disease, psoriasis, and psoriatic arthritis. His responsibilities include generating and analyzing proteomic and transcriptomic datasets from human clinical samples that directly inform dose selection decisions and mechanism of action assessments in active drug trials. Platforms he works with include Meso Scale Discovery immunoassays, digital spatial profiling, and single-cell RNA sequencing from FFPE tissue.
More on TelAve News
- The Problem With AI Isn't Compute. It's Memory
- Golden Visa Countries Outpace Eurozone Growth Over Eight Years, New La Vida Analysis Finds
- Allstream Energy Partners Announced as Official Media Partner for the 2nd Annual Permian Power Conference
- CCHR Calls Out Psychiatry's Pattern of Resistance to Antidepressant Deprescribing
- Boston Industrial Solutions Introduces New NatronĀ® 310 Hyper White UV Ink for Enhanced Printing Performance
His focus on IBD is particularly relevant given that ulcerative colitis and Crohn's disease affect an estimated 3 million Americans, with a significant portion failing to respond to existing biologic therapies. Parast holds a BS in Biochemistry from Temple University, and prior to his role at J&J, worked as an Associate Scientist II at QPS and in biopharmaceutical manufacturing at GSK.
Beyond his biomarker work, Parast is developing a deeper interest in fundamental biology, specifically the interleukin-23 receptor (IL-23R) pathway, which plays a central role in the inflammatory cascade underlying IBD and psoriatic disease. His MBA concentration in Artificial Intelligence reflects a conviction that the future of drug development will be shaped by scientists who can speak both the language of biology and machine learning.
Outside of his pharmaceutical career, Parast holds an ACSM personal trainer certification and writes about the science of training, inflammation, and recovery. His professional profile is at roohidparast.github.io and his research profile is at researchgate.net/profile/Roohid-Parast.
Source: Roohid Parast Science & Fitness
0 Comments
Latest on TelAve News
- Nevada Boxing Hall of Fame Announces 14th Annual Induction Gala Weekend Honoring Classes of 2025 and 2026
- Brosix Celebrates 20 Years of Private Team Messaging for Small and Mid-Sized Businesses
- Top 15 Mosquito-Infested Cities in Louisiana and East Texas Ranked for 2026 Mosquito Season
- From Broken to Soaring Week 40
- Finnish Political Satire Film Generates 10,000+ Cross-Platform Interactions Following Gandalf Parody Video Across TikTok, YouTube and Telegram
- AI Is Making It Easier for API-First Platforms to Connect, Partner, Reach Customers, and Grow Revenue Faster
- 2026 Editorial Freelancers Association Conference Focuses on Building Sustainable Careers
- netElastic Powers LigaT's High-Performance Broadband Expansion and IPv6 Modernization in Portugal
- Raiku launches rkuSOL with Sanctum, Kamino, Loopscale and Exponent
- Greenland Mines Ltd (N A S D A Q: GRML) Advances Strategic Growth Initiatives as Critical Minerals Demand Accelerates
- Entering the $69 Billion Animal Health Market, Delivering Record Growth, AI-Driven Healthcare Innovation, and Targeting $200 Million Revenue by 2029
- $97.9 Million Q1 Revenue Growth Reinforces Transformation Into a Global AI & Digital Services Powerhouse: IQSTEL, Inc. (N A S D A Q: IQST)
- AI Is Fueling New Growth at HP, Cisco, Dell, Intel, Nokia and More: Industry Analyst Jeff Kagan
- Boston Industrial Solutions Launches NatronĀ® 348 UV Inkjet Ink for Epson S3200 Print Heads
- Heritage at South Brunswick Unveils Luxury Resort-Style Amenities Designed for Every Generation
- CAPHRA warns push for ASEAN vape ban ignores science
- Your Mortgage Toolbox Launches Free Mortgage Calculators That Show the Real Monthly Payment and Cash Needed to Close
- ENTOUCH Recognized on Inc.'s 2026 Best Workplaces List for the Third Year Running
- P-Wave Classics Opens Pre-Orders for Volume II of Robert Bage's Hermsprong
- Tuckwell Machinery Launches New Range of Woodworking Machinery